secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hepion Pharmaceuticals, Inc. (HEPA)
CIK:        0001583771
Form:       8-K
Filed at:   2025-06-30T23:59:59+00:00
Accession:  0001641172-25-017037
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Hepion Pharmaceuticals CFO John Brancaccio resigns; interim CFO named
---------------------------------------------------------------------

- John Brancaccio resigned as CFO and director effective June 30, 2025, for personal reasons.
- Kaouthar Lbiati assumes role of Interim Chief Financial Officer as of the filing date.
- No permanent successor has been announced; company is a clinical-stage biotech (HEPA).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583771/000164117225017037/0001641172-25-017037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583771/000164117225017037/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-017037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer